1 |
Singer M, Deutschman CS, Seymour CW, et al. The third international consensus defnitions for sepsis and septic shock(sepsis-3) [J]. JAMA, 2016, 5(8):801-810.
|
2 |
Vieillard-Baron A. Septic cardiomyopathy [J]. Ann Intensive Care, 2011, 1(1): 6.
|
3 |
Beesley SJ, Weber G, Sarge T, et al. Septic cardiomyopathy [J]. Crit Care Med, 2018, 46(4): 625-634.
|
4 |
李昕原, 吴彩军, 郭楠, 等. 脓毒症心肌病的研究进展 [J]. 中国中西医结合急救, 2019, 26(3): 372-377.
|
5 |
李玉婷, 李洪祥, 张东. 脓毒性心肌病的发病率及危险因素分析 [J]. 中华急诊医学, 2019, 28(7): 836-840.
|
6 |
刘长智, 朱瑞秋, 周柱江, 等. ECMO治疗脓毒症心肌病合并心源性休克 [J]. 中华危重病急救医学, 2017, 29(12): 1140-1143.
|
7 |
Ehrman RR, Sullivan AN, Favot MJ, et al. Pathophysiology, echocardiographic evaluation, biomarker findings, and prognostic implications of septic cardiomyopathy: a review of the literature [J]. Crit Care, 2018, 22(1): 112.
|
8 |
Ravikumar N, Sayed MA, Poonsuph CJ, et al. Septic cardiomyopathy: from basics to management choices [J]. Curr Probl Cardiol, 2020, 46(4): 100767.
|
9 |
Parker MM, Shelhamer JH, Bacharach SL, et al. Profound but reversible myocardial depression in patients with septic shock [J]. Ann Intern Med, 1984, 100(4): 483-490.
|
10 |
Stanzani G, Duchen MR, Singer M. The role of mitochondria in sepsis-induced cardiomyopathy [J]. Biochim Biophys Acta Mol Basis Dis, 2019, 1865(4): 759-773.
|
11 |
Liu YC, Yu MM, Shou ST, et al. Sepsis-induced cardiomyopathy: mechanisms and treatments [J]. Front Immunol, 2017, 8: 1021.
|
12 |
赵蓉英, 许丽敏. 文献计量学发展演进与研究前沿的知识图谱探析 [J]. 中国图书馆学报, 2010, 36(5): 60-68.
|
13 |
陆宗庆, 许耀华, 张金, 等, 2010至2020年ICU谵妄领域研究进展: 基于知识可视化分析 [J]. 中华危重病急救医学杂志, 2020, 32(7): 785-791.
|
14 |
陈超美, 陈悦, 侯剑华, 等. CiteSpace Ⅱ: 科学文献中新趋势与新动态的识别与可视化 [J]. 情报学报, 2009, 28(3): 401-421.
|
15 |
Joseph LC, Reyes MV, Lakkadi KR, et al. PKCδ causes sepsis-induced cardiomyopathy by inducing mitochondrial dysfunction [J]. Am J Physiol Heart Circ Physiol, 2020, 318(4): H778-H786.
|
16 |
Antonucci E, Fiaccadori E, Donadello K, et al. Myocardial depression in sepsis: from pathogenesis to clinical manifestations and treatment [J]. J Crit Care, 2014, 29(4): 500-511.
|
17 |
L'Heureux M, Sternberg M, Brath L, et al. Sepsis-induced cardiomyopathy: a comprehensive review [J]. Curr Cardiol Rep, 2020, 22(5): 35.
|
18 |
Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012 [J]. Intensive Care Med, 2013, 39(2): 165-228.
|
19 |
Landesberg G, Gilon D, Meroz Y, et al. Diastolic dysfunction and mortality in severe sepsis and septic shock [J]. Eur Heart J, 2012, 33(7): 895-903.
|
20 |
Lin H, Wang W, Lee M, et al. Current status of septic cardiomyopathy: basic science and clinical progress [J]. Front Pharmacol, 2020, 11: 210.
|
21 |
Kumar A, Haery C, Parrillo JE. Myocardial dysfunction in septic shock [J]. Crit Care Clin, 2000, 16(2): 251-287.
|
22 |
Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016 [J]. Crit Care Med, 2017, 45(3): 486-552.
|
23 |
Rudiger A, Singer M. Mechanisms of sepsis-induced cardiac dysfunction [J]. Crit Care Med, 2007, 35(6): 1599-1608.
|
24 |
Hou D, Bi X, Mao Z, et al. Biomaterials research of China from 2013 to 2017 based on bibliometrics and visualization analysis [J]. Peer J, 2019, 7: e6859.
|